CYP3A activity and expression in nonalcoholic fatty liver disease
SJ Woolsey, SE Mansell, RB Kim, RG Tirona… - Drug Metabolism and …, 2015 - ASPET
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western
world, given its association with obesity, type 2 diabetes, and dyslipidemia. Medications are …
world, given its association with obesity, type 2 diabetes, and dyslipidemia. Medications are …
Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters
…, BL Morse, BF Leake, A Wilson, SE Mansell… - Molecular …, 2017 - ACS Publications
Trimethylamine-N-oxide (TMAO) is a recently identified predictor of cardiovascular and
chronic kidney disease. TMAO is primarily generated through gut-microbiome mediated …
chronic kidney disease. TMAO is primarily generated through gut-microbiome mediated …
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)
WA Teft, SE Mansell, RB Kim - Drug metabolism and disposition, 2011 - ASPET
Tamoxifen is widely prescribed to patients with estrogen receptor-positive breast cancer, and
it is a prodrug that requires bioactivation by cytochrome P450 enzymes CYP2D6 and 3A4 …
it is a prodrug that requires bioactivation by cytochrome P450 enzymes CYP2D6 and 3A4 …
Fexofenadine and rosuvastatin pharmacokinetics in mice with targeted disruption of organic anion transporting polypeptide 2B1
Organic anion transporting polypeptide 2B1 (OATP2B1) is a widely expressed membrane
transporter with diverse substrate specificity. In vitro and clinical studies suggest a role for …
transporter with diverse substrate specificity. In vitro and clinical studies suggest a role for …
Absence of both MDR 1 (ABCB 1) and Breast Cancer Resistance Protein (ABCG 2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous …
IY Gong, SE Mansell, RB Kim - Basic & clinical pharmacology & …, 2013 - Wiley Online Library
Rivaroxaban is a novel factor 10a inhibitor, where hepatic metabolism and renal clearance
account for its overall disposition. Renal impairment is known to increase rivaroxaban‐…
account for its overall disposition. Renal impairment is known to increase rivaroxaban‐…
A fibroblast growth factor 21–pregnane X receptor pathway downregulates hepatic CYP3A4 in nonalcoholic fatty liver disease
SJ Woolsey, MD Beaton, SE Mansell… - Molecular …, 2016 - ASPET
Nonalcoholic fatty liver disease (NAFLD) alters drug response. We previously reported that
NAFLD is associated with reduced in vivo CYP3A drug-metabolism activity and hepatic …
NAFLD is associated with reduced in vivo CYP3A drug-metabolism activity and hepatic …
[HTML][HTML] Effect of ticagrelor versus clopidogrel on vascular reactivity
…, R Lavi, I Gong, S D'Alfonso, SE Mansell… - Journal of the American …, 2017 - jacc.org
Ticagrelor has shown superiority compared with clopidogrel in reducing cardiovascular
events (1). Although some of the clinical benefits of ticagrelor may simply reflect its potency in …
events (1). Although some of the clinical benefits of ticagrelor may simply reflect its potency in …
Mouse NTCP–Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice
…, RH Ho, BF Leake, CL Schmerk, SE Mansell… - The AAPS Journal, 2021 - Springer
Statins competitively inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase,
a rate-limiting enzyme in cholesterol biosynthesis. Their primary pharmacological effect is …
a rate-limiting enzyme in cholesterol biosynthesis. Their primary pharmacological effect is …
[PDF][PDF] Accelerated Communication Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
WA Teft, SE Mansell, RB Kim - DRUG METABOLISM AND …, 2011 - academia.edu
Tamoxifen is widely prescribed to patients with estrogen receptor-positive breast cancer, and
it is a prodrug that requires bioactivation by cytochrome P450 enzymes CYP2D6 and 3A4 …
it is a prodrug that requires bioactivation by cytochrome P450 enzymes CYP2D6 and 3A4 …
[PDF][PDF] Cytochrome P450 3A Activity and Expression in Non-Alcoholic Fatty Liver Disease
SJ Woolsey, SE Mansell, RB Kim, RG Tirona… - schulich.uwo.ca
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the